Another study of 589 stage III BRAF-mutant melanoma patients revealed that treatment with anti-PD1 monotherapy resulted in a similar OS compared to treatment with dabrafenib plus trametinib, and the median relapse-free survival was 51 months in the dabrafenib + trametinib treatment group compared to 44.8 months in the anti-PD-1 monotherapy group (8). The gene discussed is BRAF; the disease is melanoma.